Alexion reports positive asfotase alfa interim results for infants
This article was originally published in Scrip
Executive Summary
Investors had another ho-hum reaction to good news for asfotase alfa from Alexion Pharmaceuticals after the company reported interim data from an open-label Phase II study that showed statistically significant improvements in skeletal mineralization after 24 weeks of treatment for 13 infants (p=0.001) suffering from the life-threatening genetic disease hypophosphatasia (HPP).
You may also be interested in...
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Need a specific report? 1000+ reports available
Buy Reports